Breast Recurrence Score Test Market Outlook:
Breast Recurrence Score Test Market size was over USD 4.16 billion in 2025 and is poised to exceed USD 7.66 billion by 2035, growing at over 6.3% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of breast recurrence score test is estimated at USD 4.4 billion.
The increasing emphasis on value-based healthcare is one of the main growth drivers fueling the market. The shift towards value-based healthcare is transforming the landscape of medical practices, emphasizing the importance of outcomes that matter most to patients. In the context of breast cancer, where treatment decisions have profound implications for patients' quality of life, value-based healthcare encourages the adoption of diagnostic tools that not only improve clinical outcomes but also contribute to cost-effectiveness and resource optimization. A study published demonstrated that the use of the Oncotype DX Breast Recurrence Score Test led to a significant reduction in chemotherapy use among patients with early-stage, estrogen receptor-positive breast cancer. The study reported a 46.6% reduction in the use of chemotherapy.
The breast recurrence score test is a diagnostic tool used in the field of breast cancer management to assess the risk of recurrence in early-stage, hormone receptor-positive breast cancer patients. This test provides valuable information to help guide treatment decisions, particularly with regard to whether or not to administer chemotherapy in addition to hormonal therapy. The market for breast recurrence score testing includes competition from other genetic tests and platforms aimed at assessing breast cancer prognosis and treatment planning.
